Cargando…

Cost-effectiveness analysis of dapagliflozin for the treatment of type 2 diabetes mellitus in Spain: results of the DECLARE-TIMI 58 study

BACKGROUND: The objective of this study was to carry out a cost-effectiveness analysis of dapagliflozin, as an add-on therapy to standard of care (SoC), for the treatment of type 2 diabetes mellitus (T2DM) in Spain, based on the results of the DECLARE-TIMI 58 trial. METHODS: A discrete event simulat...

Descripción completa

Detalles Bibliográficos
Autores principales:	Escobar, Carlos, Morales, Cristóbal, Capel, Margarita, Simón, Susana, Pérez-Alcántara, Ferran, Pomares, Elisenda
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8851809/ https://www.ncbi.nlm.nih.gov/pubmed/35177053 http://dx.doi.org/10.1186/s12913-022-07567-5

Ejemplares similares

The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58
por: Mosenzon, Ofri, et al.
Publicado: (2021)

The cost‐effectiveness of dapagliflozin in treating high‐risk patients with type 2 diabetes mellitus: An economic evaluation using data from the DECLARE‐TIMI 58 trial
por: McEwan, Phil, et al.
Publicado: (2021)

Dapagliflozin and Prevention of Kidney Disease Among Patients With Type 2 Diabetes: Post Hoc Analyses From the DECLARE-TIMI 58 Trial
por: Mosenzon, Ofri, et al.
Publicado: (2022)

Dapagliflozin and cardiovascular mortality and disease outcomes in a population with type 2 diabetes similar to that of the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

Dapagliflozin vs non‐SGLT‐2i treatment is associated with lower healthcare costs in type 2 diabetes patients similar to participants in the DECLARE‐TIMI 58 trial: A nationwide observational study
por: Norhammar, Anna, et al.
Publicado: (2019)

SAVOR-TIMI to DECLARE-TIMI: A Review on Cardiovascular Outcome Trials of Incretin-modulators and Gliflozins
por: Singh, Awadhesh K., et al.
Publicado: (2019)

Costs and healthcare utilisation of patients with heart failure in Spain
por: Escobar, Carlos, et al.
Publicado: (2020)

Costs and healthcare utilisation of patients with chronic kidney disease in Spain
por: Escobar, Carlos, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Exenatide versus GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Mellitus
por: Capel, Margarita, et al.
Publicado: (2019)

Dynamic TIMI Risk Score for STEMI
por: Amin, Sameer T., et al.
Publicado: (2013)

Cost-Effectiveness of Liraglutide Versus Dapagliflozin for the Treatment of Patients with Type 2 Diabetes Mellitus in the UK
por: Vega-Hernandez, Gabriela, et al.
Publicado: (2017)

TIMI perfusion grade compared to TIMI flow in prediction of infarct size and microvascular obstruction measured by contrast-enhanced MRI
por: Fuernau, Georg FK, et al.
Publicado: (2009)

Regional and global impacts of the 2007 Port-of-Spain Declaration on noncommunicable diseases
por: Kirton, John, et al.
Publicado: (2019)

The cost‐effectiveness of dapagliflozin compared to DPP‐4 inhibitors in the treatment of type 2 diabetes mellitus in the Netherlands
por: Van der Linden, N., et al.
Publicado: (2020)

Cost-Effectiveness Analysis of Insulin Detemir Compared to Neutral Protamine Hagedorn (NPH) in Patients with Type 1 and Type 2 Diabetes Mellitus in Spain
por: Morales, Cristóbal, et al.
Publicado: (2015)

Importance of the TIMI frame count: implications for future trials
por: Appleby, Mark A, et al.
Publicado: (2000)

Dapagliflozin: Cardiovascular Safety and Benefits in Type 2 Diabetes Mellitus
por: Saleem, Fatima
Publicado: (2017)

‘Facts that are declared proven’: sexual violence, forensic medicine, and the courtroom in early Francoist Spain.
por: Wright, Stephanie
Publicado: (2023)

Declarations
Publicado: (2015)

Expert Opinion About the Pharmacoeconomic Edge of Low-Cost Dapagliflozin in Type 2 Diabetes Mellitus in Indian Clinical Settings
por: Sharma, Kamal, et al.
Publicado: (2021)

Far Beyond Declarative and Non-Declarative Memories
por: Dere, Ekrem, et al.
Publicado: (2014)

Implications of the PEGASUS-TIMI 54 trial for US clinical practice
por: Bradley, Steven M, et al.
Publicado: (2017)

The 2007 Caribbean Community Port-of-Spain Declaration on noncommunicable diseases: an overview of a multidisciplinary evaluation
por: Samuels, T. Alafia, et al.
Publicado: (2018)

Ten years of the Port of Spain Declaration: Lessons learned from tackling noncommunicable diseases in the Caribbean
Publicado: (2018)

Updated Database and Trends of Declared Low- and No-Calorie Sweeteners From Foods and Beverages Marketed in Spain
por: Samaniego-Vaesken, Mª de Lourdes, et al.
Publicado: (2021)

Medical consumption compared for TIMI and HEART score in chest pain patients at the emergency department: a retrospective cost analysis
por: Nieuwets, A, et al.
Publicado: (2016)

Declared Reasons for Cessation of Breastfeeding during the First Year of Life: An Analysis Based on a Cohort Study in Northern Spain
por: Lechosa-Muñiz, Carolina, et al.
Publicado: (2021)

Comparison of Prediction Between TIMI (Thrombolysis in Myocardial Infarction) Risk Score and Modified TIMI Risk Score in Discharged Patients From Emergency Department With Atypical Chest Pain
por: Abbasnezhad, Mohsen, et al.
Publicado: (2014)

Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease
por: Bergmark, Brian A., et al.
Publicado: (2018)

Reduction in Subtypes and Sizes of Myocardial Infarction With Ticagrelor in PEGASUS–TIMI 54
por: Bonaca, Marc P., et al.
Publicado: (2018)

Cost-effectiveness of Dapagliflozin for the Treatment of Heart Failure With Reduced Ejection Fraction
por: Isaza, Nicolas, et al.
Publicado: (2021)

Declarative Networking
por: Loo, Boon Thau, et al.
Publicado: (2012)

DECLARATION TO COUNCIL
por: Staff Association
Publicado: (2015)

The Hanoi Declaration
por: Natsume, Nagato, et al.
Publicado: (2014)

Declaration of Independence
Publicado: (1860)

A Comparison of the Pharmacokinetics and Safety of Dapagliflozin Formate, an Ester Prodrug of Dapagliflozin, to Dapagliflozin Propanediol Monohydrate in Healthy Subjects
por: Kim, Hyun Chul, et al.
Publicado: (2023)

The Barcelona declaration on bridging knowledge in long-term care and support. Barcelona (Spain), March 7, 2009
por: Salvador-Carulla, Luis, et al.
Publicado: (2010)

The Barcelona declaration on bridging knowledge in long-term care and support. Barcelona (Spain), March 7, 2009
por: Salvador-Carulla, Luis, et al.
Publicado: (2009)

Communication strategy to disseminate the results of the evaluation of the Port-of-Spain Declaration (POSDEVAL) across multiple audiences in the Caribbean
por: Greaves, Natalie S., et al.
Publicado: (2018)

Dapagliflozin as an adjunct therapy to insulin in the treatment of patients with type 1 diabetes mellitus
por: Tamez, Hector E., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_k128rcv5q76nal5mbfdrm5d09q